Wird geladen...
Bleeding by Bruton Tyrosine Kinase-Inhibitors: Dependency on Drug Type and Disease
SIMPLE SUMMARY: Bruton tyrosine kinase (Btk) is expressed in B-lymphocytes, myeloid cells and platelets. Since the launch of the first in class Btk-inhibitor (BTKi) ibrutinib in 2013, the list of indications and further drug candidates has expanded greatly. BTKi are not only used to treat patients w...
Gespeichert in:
| Veröffentlicht in: | Cancers (Basel) |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
MDPI
2021
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7961939/ https://ncbi.nlm.nih.gov/pubmed/33806595 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13051103 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|